Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe UK EUR

Danaher Corporation (DAPD.XC)

169.46
0.00
(0.00%)
As of April 15 at 3:38:17 PM GMT+1. Market Open.
Loading Chart for DAPD.XC
  • Previous Close 169.46
  • Open 169.46
  • Bid 168.40 x --
  • Ask 174.52 x --
  • Day's Range 169.46 - 169.46
  • 52 Week Range 169.46 - 246.90
  • Volume 22
  • Avg. Volume 5
  • Market Cap (intraday) 124.778B
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) 37.16
  • EPS (TTM) 4.56
  • Earnings Date Jul 21, 2025 - Jul 25, 2025
  • Forward Dividend & Yield 1.13 (0.66%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

www.danaher.com

61,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DAPD.XC

View More

Performance Overview: DAPD.XC

Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DAPD.XC
24.27%
S&P 500 (^GSPC)
3.93%

1-Year Return

DAPD.XC
25.44%
S&P 500 (^GSPC)
10.19%

3-Year Return

DAPD.XC
16.92%
S&P 500 (^GSPC)
36.26%

5-Year Return

DAPD.XC
16.92%
S&P 500 (^GSPC)
96.98%

Compare To: DAPD.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DAPD.XC

View More

Valuation Measures

Annual
As of 5/5/2025
  • Market Cap

    125.01B

  • Enterprise Value

    137.83B

  • Trailing P/E

    37.11

  • Forward P/E

    25.38

  • PEG Ratio (5yr expected)

    1.88

  • Price/Sales (ttm)

    5.87

  • Price/Book (mrq)

    2.70

  • Enterprise Value/Revenue

    6.54

  • Enterprise Value/EBITDA

    21.80

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.81%

  • Return on Assets (ttm)

    3.93%

  • Return on Equity (ttm)

    7.22%

  • Revenue (ttm)

    23.82B

  • Net Income Avi to Common (ttm)

    3.76B

  • Diluted EPS (ttm)

    4.56

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.99B

  • Total Debt/Equity (mrq)

    34.56%

  • Levered Free Cash Flow (ttm)

    4.23B

Research Analysis: DAPD.XC

View More

Company Insights: DAPD.XC

Research Reports: DAPD.XC

View More